Welcome To Our Website!SALES DEPT:info@puresynmr.com

ProductsHome>Products

SARMS/YK11/ ((17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carbo

CAS# 431579-34-9

Product Price: Contact us to get the latest price

Product Specification : 98%

Minmum Order Quantity : >50g

Sample Requirement : Free Sample / Freight Charged / to final agreement

Product No.: PURYK11

Product Introduction

What is YK11?

(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist. as well as by dihydrotestosterone (DHT).

YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.

Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won’t have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.

How it works?

Animal Research:

In direct comparison to to LGD-4033 as the reference for assay upon animal models of anabolism and androgenicity, YK-11 demonstrated higher efficacy withing anabolic parameters and lesser androgenicity at equivalent dosages.

It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as growth differentiation factor 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin inhibitors are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-hormones, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.

Dosages and Suggestion

Recommended maximum dose YK11 is require dosages of 2.0-5.0mg b.i.d. in males and 0.5mg-2mg b.i.d. in females to achieve optimal effects in humans for the noted indications.

SARMS We offer

AICAR

2627-69-2

acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown

MK2866

841205-47-8

medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.

MK-677

15972-10-0

A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly

LGD-4033

1165910-22-4

pharmacological profile similar to that of enobosarm, Ostarine,MK-2866

GW501516

317318-70-0

For obesity, diabetes, dyslipidemia and cardiovascular disease

Andarine(S4)

401900-40-0

partial agonist, intended mainly for treatment of benign prostatic hypertrophy

SR9009

1379686-30-2

under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice

SR9011

1379686-30-2

For obesity, diabetes, dyslipidemia and cardiovascular disease

RAD140

1182367-47-0

New generation for gaining mass and cutting edges

YK11

366508-78-3

431579-34-9

a SARM and myostatin inhibitor in one

GHRP-2

158861-67-7

Growth Hormone Releasing Peptide-2

GHRP-6

87616-84-0

Growth Hormone Releasing Peptide-6

TB500

107761-42-2

Thymosin beta 4

SM130,686

/

/

Copyright © 2012 SYNMR All Rights Reserved. Design by Baiqi